What happened
Researchers have developed a new drug aimed at preventing muscle loss associated with the use of weight-loss medications like Ozempic, a phenomenon informally known as “Ozempic butt.” The drug works by targeting the biological pathways that cause muscle atrophy during rapid fat loss, helping patients maintain muscle mass while reducing fat. Clinical trials have shown promising results, indicating that patients using the drug alongside Ozempic maintain stronger gluteal muscles and experience fewer physical side effects.
Why it matters
As medications like Ozempic become increasingly popular for weight management, an unintended side effect—significant muscle loss leading to a sunken or sagging appearance in the buttocks—has raised concerns among users and healthcare providers. Muscle loss not only affects physical appearance but can also impair mobility and overall health. This new drug addresses a critical gap by preserving muscle mass, thereby improving both the aesthetic outcomes and long-term health of patients undergoing treatment for obesity or type 2 diabetes.
Background
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed to treat type 2 diabetes. It has gained popularity for its strong weight-loss effects, often resulting in rapid fat reduction. However, doctors and patients have reported unintended muscle loss, especially in the gluteal region, leading to the colloquial term “Ozempic butt.” This muscle atrophy can cause a less toned appearance and difficulties in daily activities. Until now, there were limited options to counteract these effects without compromising the medication’s benefits.
Questions and Answers
Q: What causes the muscle loss known as “Ozempic butt”?
A: Muscle loss occurs because rapid fat reduction from GLP-1 drugs like Ozempic can also signal the body to break down muscle tissue for energy, leading to atrophy especially in areas like the buttocks.
Q: How does the new drug prevent muscle loss?
A: The drug targets specific cellular pathways involved in muscle degradation, inhibiting the process that leads to muscle breakdown during rapid weight loss without affecting fat reduction.
Q: Is the new drug safe and available to the public?
A: Clinical trials indicate the drug is safe when used alongside Ozempic, but it is still undergoing regulatory review and is not yet widely available.
Q: Will this drug work with other weight-loss medications?
A: Early research is focused on Ozempic, but scientists are exploring its potential to support muscle retention with other similar GLP-1 receptor agonists.
Q: Does the drug affect the effectiveness of Ozempic’s weight loss benefits?
A: No, studies show it helps preserve muscle without interfering with fat loss or glycemic control provided by Ozempic.
Source: https://www.bbc.com/news/articles/c62r285l46eo?at_medium=RSS&at_campaign=rss